On Friday, CADTH’s Pharmaceutical Reviews Update – Issue 43 introduced a number of updates pertaining to its Reimbursement Reviews procedures. These include: Budget Impact Analysis (BIA) Consultation: CADTH is seeking stakeholder feedback on its draft BIA template tool. The tool is an optional resource to ... Read More


PDCI released a new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada. In this Issue:... Read More



Happy Holidays from PDCI!

As another memorable year draws to a close, the team at PDCI Market Access would like to express its sincere gratitude and appreciation for all our clients, partners, and people who support us in our purpose to improve health outcomes for all.We hope your holiday season is filled ... Read More


On September 27, 2023, the Patented Medicine Prices Review Board (PMPRB) published its final decision regarding the Amended Interim Guidance first proposed on June 20, 2023.Effective immediately, the proposed amendments to the Interim Guidance are implemented without changes, notwithstanding the concerns raised by many of the ... Read More


The pan-Canadian Pharmaceutical Alliance (pCPA) introduced its proposed pCPA Temporary Access Process (pTAP) and invited stakeholders’ input on the process, its principles and conditions by August 18th, 2023.   The proposed pTAP and its associated principles are intended to inform pCPA negotiations and product listing agreements for ... Read More


On June 5, 2023, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced a series of process improvements it plans to explore or add to its drug reimbursement review process. These changes - aimed at gaining efficiencies, reducing timelines and improving transparency – include:... Read More


On November 10, 2022, among other procedural updates included in the CADTH Pharmaceutical Reviews Update Issue 32, CADTH published its Real-World Evidence (RWE) Steering Committee’s anticipated Proposed RWE Reporting Guidance and initiated a public consultation on the guidance open now through January 6, 2023.What to know: The ... Read More


PDCI is congratulating its Managing Director, Kaitlyn Proulx, as she begins parental leave effective November 28, 2022.Since joining PDCI in 2010, Kaitlyn has demonstrated incredible strategic insights advising clients on optimizing pricing and market access in Canada. Since becoming Managing Director in 2017, Kaitlyn has ... Read More


The Patented Medicine Prices Review Board (PMPRB) today, Ocober 6, 2022, released its draft PMPRB Guidelines with a 60-day consultation period running until December 5, 2022. PMPRB maintains that final Guidelines will be issued by end of this year and previously indicated its intent for new Guidelines ... Read More


On August 18, 2022, PMPRB announced its decisions regarding Price Regulation of patented medicines during the ‘Interim Period’, between July 1, 2022 and when a final set of price regulatory guidelines is published. The PMPRB has decided to move forward with earlier proposals drafted June 30th, 2022, and ... Read More